Objetivo Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each year, yet key challenges remain in order to guarantee the future health of the expanding and ageing global population. For example, effective vaccines are still required for Respiratory Syncytial Virus (RSV) and Group B Streptococcus (GBS), both of which cause significant hospitalisations globally each year. RSV is a common cause of respiratory disease among all age groups; annually it results in an estimated 33.8 million acute lower respiratory tract infections (resulting in 66,000-199,000 deaths) and among the elderly, it results in as many hospitalisations as influenza. Group B Streptococcus (GBS) infections also pose a serious risk; GBS is a leading cause of invasive infections in pregnant women, new-born infants, and the elderly. To meet the challenge of developing fit-for-purpose, age-appropriate vaccines against these disease targets, this EID will bring together two cross-sector, world leading teams – GSK Vaccines S.r.L and the University of Strathclyde – with the objective to equip the next generation of vaccinologists with the skills and tools to deliver vaccines for the 21st Century. GSK Vaccines S.r.L is a global leader in vaccine research, development and production and will work in partnership with the vaccine team within USTRATH and the Strathclyde Institute of Pharmacy and Biomedical Sciences, who have an international track-record of translatable and innovative research in immunology, immunomodulation, structural biology, and formulation design and pharmaceutical engineering of vaccine systems. PHA-ST-TRAIN-VAC will deliver a unique, multidisciplinary and intersectoral training programme to develop and equip four early stage researchers with the required skills and entrepreneurship to develop new vaccines to protect against RSV and GBS, in a formulation tailored to the age of the patient. Ámbito científico medical and health sciencesbasic medicineimmunologyimmunisationmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programa(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers Tema(s) MSCA-ITN-2015-EID - Marie Skłodowska-Curie Innovative Training Networks (ITN-EID) Convocatoria de propuestas H2020-MSCA-ITN-2015 Consulte otros proyectos de esta convocatoria Régimen de financiación MSCA-ITN-EID - European Industrial Doctorates Coordinador UNIVERSITY OF STRATHCLYDE Aportación neta de la UEn € 546 575,76 Dirección Richmond Street 16 G1 1XQ Glasgow Reino Unido Ver en el mapa Región Scotland West Central Scotland Glasgow City Tipo de actividad Higher or Secondary Education Establishments Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 546 575,76 Participantes (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo GLAXOSMITHKLINE VACCINES SRL Italia Aportación neta de la UEn € 516 122,64 Dirección VIA FIORENTINA 1 53100 SIENA Ver en el mapa Región Centro (IT) Toscana Siena Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 516 122,64
